Pharsight

Veregen generic

Veregen is an ointment used for the treatment of genital warts, owned by Ani Pharms. The active ingredient in this medication is sinecatechins. Veregen was first authorized for market use on October 31, 2006. The drug holds a total of 3 patents, out of which 1 has already expired.

When will Veregen generic be available?

The generic version of Veregen is likely to be released after October 2, 2026. This release is due to the expiry of the last patent, US7858662, which is titled 'Medicament for the treatment of viral skin and tumour diseases' and expires on October 2, 2026.

Veregen uses

Veregen, which contains sinecatechins, is primarily used for the treatment of genital warts. The active ingredient sinecatechins is effective in combating the virus that causes this condition.

Veregen patent expiration

Veregen holds 3 patents. The last one, US7858662 titled 'Medicament for the treatment of viral skin and tumour diseases', is set to expire on October 2, 2026. Hence, the generics of Veregen will be available after this date. One patent, US10434059, has already expired. Below are the details of the patents:

Litigations filed on Veregen

Veregen dosage

Want to ask something?